Favorable outcome for children with paratesticular alveolar history Rhabdomyosarcoma [3]

Pediatric Blood and Cancer

Volumn 43, Issue 2, 2004, Pages 180-

  Anderson, James R ^a   Meyer, William H ^b   Wiener, Eugene S ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; HUMAN; LETTER; PRIORITY JOURNAL; RECURRENT CANCER; RHABDOMYOSARCOMA; TESTIS TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHILD; HUMANS; MALE; RHABDOMYOSARCOMA, ALVEOLAR; SURVIVAL RATE; TESTICULAR NEOPLASMS;

EID: 3042757584     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20087     Document Type: Letter

References (3)

1. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-630.
2. Donaldson SS, Asmar L, Breneman J, et al. Hyperfractionated radiation in children with rhabdomyosarcoma: Results of an Intergroup Rhabdomyosarcoma Pilot Study. Int J Radiat Oncol Biol Phys 1995;32(4):903-911.
3. Crist WM, Anderson JR, Mesa JL, et al. Intergroup Rhabdomyosarcoma Study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-3102.